2. Academic Validation
  3. Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats

Oxiracetam can improve cognitive impairment after chronic cerebral hypoperfusion in rats

  • Psychiatry Res. 2016 Dec 30:246:284-292. doi: 10.1016/j.psychres.2016.10.006.
Xiao-Li Yao 1,  Zhao-Hui Yao 2,  Li Li 3,  Li Nie 3,  Shao-Feng Zhang 3
Affiliations

Affiliations

  • 1 Department of Neurology, Central hospital of Zhengzhou, #195 Tongbo Road, Zhengzhou, China; Department of Neurology, Renmin hospital of Wuhan University, #238 Jiefang Road, Wuhan, China.
  • 2 Department of Geriatrics, Renmin hospital of Wuhan University, #238 Jiefang Road, Wuhan, China; Department of Neurology, Renmin hospital of Wuhan University, #238 Jiefang Road, Wuhan, China. Electronic address: yaozhaohui2004@126.com.
  • 3 Department of Geriatrics, Renmin hospital of Wuhan University, #238 Jiefang Road, Wuhan, China; Department of Neurology, Renmin hospital of Wuhan University, #238 Jiefang Road, Wuhan, China.
PMID: 27741481 DOI: 10.1016/j.psychres.2016.10.006
Abstract

Chronic cerebral hypoperfusion (CCH) induces cognitive deficits. Although CCH can be improved, cognitive impairment is not improved accordingly. To date, many studies have focused on investigating the pathophysiological mechanisms of CCH; however, the treatment of the induced cognitive impairment remains ineffective. Thus, the mechanisms underlying cognitive impairment after CCH and potential agents for treating this impairment need to be explored further. Oxiracetam is a nootropic drug that improves clinical outcomes for some central nervous system (CNS) disorders. Whether it can improve cognitive impairment after CCH is unknown. In this study, we used behavioural methods, electrophysiology, biochemistry, histopathological staining and transmission electron microscope to investigate rat's cognitive impairment by CCH, and found that Oxiracetam could improve CCH-induced cognitive impairment and prevent deficits of neural plasticity, white matter lesions, and synaptic ultrastructure. These results suggest that Oxiracetam may be effective as a potential agent against CCH-induced cognitive impairment.

Keywords

Chronic cerebral hypoperfusion; Cognitive impairment; Oxiracetam.

Figures
Products